Business Context and Reporting Period
This Form 8-K Current Report was filed by Phio Pharmaceuticals Corp. on July 1, 2024, regarding events occurring between June 17, 2024, and July 1, 2024. The filing details the approval and implementation of a reverse stock split of the Company's common stock.
Key Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on corporate governance and capital structure adjustments.
Material Changes
- Reverse Stock Split Approval: Stockholders approved a reverse stock split at the Annual Meeting on June 17, 2024, with a ratio range of 1-for-2 to 1-for-9.
- Ratio Determination: On June 25, 2024, the Board of Directors fixed the ratio at 1-for-9.
- Implementation: The Certificate of Amendment was filed with the Delaware Secretary of State on July 1, 2024. The split is effective as of 12:01 a.m. Eastern Time on July 5, 2024.
- Share Count Reduction: The number of issued and outstanding shares will be reduced from approximately 4.6 million to approximately 0.5 million shares.
- Trading Details: Post-split trading on The Nasdaq Capital Market begins July 5, 2024, under the symbol "PHIO" with a new CUSIP number (71880W501).
Guidance, Outlook, and Unusual Items
The filing contains no financial guidance, outlook, or management commentary regarding future business performance. The document outlines specific mechanics for the reverse stock split, including:
- Fractional Shares: No fractional shares will be issued; holders entitled to fractions will receive a cash payment based on the closing price on the last trading day prior to effectiveness.
- Equity Adjustments: Exercise prices and share counts for outstanding equity awards and warrants will be proportionately adjusted.
- Authorized Shares: The number of authorized shares remains unchanged, increasing the number of shares available for issuance relative to outstanding shares.
Investor Verification Checklist
- Verify the effective date of the reverse stock split (July 5, 2024) and the start of post-split trading.
- Confirm the new CUSIP number (71880W501) for trading and settlement purposes.
- Review instructions from brokers or Computershare regarding the exchange of pre-split shares and cash payments for fractional interests.
- Check for proportionate adjustments to any held options, warrants, or equity awards.